Location History:
- Koln, DE (1997 - 2000)
- Cologne, DE (1998 - 2000)
- Köln, DE (2001 - 2006)
Company Filing History:
9 out of 1,289 
4 out of 12,160 
3 out of 61 
Years Active: 1997-2006
Title: The Innovations of Jeff Schell
Introduction
Jeff Schell is a prominent inventor based in Cologne, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of transgenic organisms. With a total of 15 patents to his name, Schell's work has had a profound impact on agricultural science and gene therapy.
Latest Patents
One of his latest patents is for a transgenic pathogen-resistant organism. This organism's genome contains at least two different genes under the control of active promoters that exhibit pathogen-inhibiting action. The synergistic effect of these genes is particularly evident when they code for products such as chitinase (ChiS, ChiG), glucanase (GluG), protein synthesis inhibitor (PSI), and antifungal protein (AFP). Another notable patent involves the stimulation of homologous recombination in eukaryotic organisms or cells by recombination promoting enzymes. This invention relates to a novel process for producing transgenic organisms or cells, which can be used for curing impairments caused by environmental influences in plants and for gene therapy in mammals.
Career Highlights
Throughout his career, Jeff Schell has worked with esteemed organizations such as the Max Planck Society for the Advancement of Science and Bayer Aktiengesellschaft. His innovative research has paved the way for advancements in genetic engineering and plant biotechnology.
Collaborations
Schell has collaborated with notable colleagues, including Guido Jach and John Mundy. Their combined expertise has contributed to the success of various projects in the field of biotechnology.
Conclusion
Jeff Schell's contributions to the field of biotechnology through his innovative patents and collaborations have established him as a leading figure in the industry. His work continues to influence advancements in transgenic organisms and gene therapy.